To include your compound in the COVID-19 Resource Center, submit it here.

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

MOMA plans to take a systematic approach to surveying a class of enzymes involved in cellular processes

Third Rock Ventures led a syndicate that invested $86 million in a series A round for MOMA Therapeutics, a newly launched start-up that will seek to interrogate a class of "molecular machines" that drive cellular processes and develop small molecules that modulate them.

The thinking is that by looking at stepwise changes in protein conformation, the company can examine intracellular mechanisms associated with disease states, discover targets through which those mechanisms' function can be disrupted,

Read the full 740 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE